Log in to search using one of your social media accounts:


Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer

Purpose of review The therapeutic armamentarium for advanced non-small-cell lung cancer has evolved considerably over the past years. Immune checkpoint inhibitors targeting programmed cell death-1 such as pembrolizumab and nivolumab or programmed cell death ligand 1 such as atezolizumab, durvalumab and avelumab have shown favorable efficacy results in this patient population in the first-line and second-line setting. These immunotherapies are associated with a distinct toxicity profile based on autoimmune organ toxicity which is a new challenge for supportive care during treatment with these drugs. Recent findings The differential diagnosis of events occurring during immune checkpoint inhibitor treatment is broad: they can be due to immune-related or nonimmune-related adverse events, atypical tumor responses (pseudoprogression or hyperprogression) or events related to comorbidities or other treatments. Summary The management of these patients includes a thorough baseline clinical, biological and radiologic evaluation, patient education, correct follow-up and management by a multidisciplinary team with a central role for the medical oncologist. Immune-related toxicities should be managed according to available guidelines.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: LUNG AND MEDIASTINUM: Edited by Robert Pirker Source Type: research

Related Links:

Authors: Re MD, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Maio MD, Petrini I, Danesi R Abstract Rationale: KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in human cancer. Despite KRAS mutations were identified in Non Small Cell Lung Cancers (NSCLCs) more than 20 years ago, selective and specific inhibitors aimed at directly abrogating KRAS activity are not yet available. Nevertheless, many therapeutic approaches have been developed potentially useful to treat NSCLC patients mutated for KRAS and refractory to both standard chemotherapy and targeted therapies.The focus ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Immunotherapy,Volume 10, Issue 5, Page 403-410, April 2018.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
ConclusionsSimplified methodology to grade OS and weigh value of anticancer drugs was proposed. In 2nd-line non-squamous NSCLC, value of Doc, Nivo, Atezo and Pembro regardless of PDL-1 expression were limited and modest. Enrichment of PD-L1 resulted in unprecedented OS, improved grades and enhanced value at seemingly justifiable costs.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Opinion statementNext-generation sequencing (NGS) of circulating tumor DNA (ctDNA) is a novel technology that can complement tumor tissue NGS and has the potential to influence diagnosis and treatment of both localized and metastatic renal cell carcinoma (mRCC). ctDNA NGS is an attractive alternative to tumor tissue NGS because it circumvents the need for repeated, invasive tissue biopsies while providing a contemporary mutational profile of a patient ’s tumors. While the role of ctDNA NGS in non-small cell lung cancer and colorectal cancer is well established, studies of ctDNA NGS in mRCC are only hypothesis-generat...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
(Reuters) - The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's, immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The therapeutic approach for the second-line treatment of patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations has been revolutionized by the recent approval of new effective ...
Source: BMC Medicine - Category: Internal Medicine Authors: Tags: Commentary Source Type: research
AbstractPurpose of reviewStage IV non-small cell lung cancer (NSCLC) is a heterogenic disease with constant challenges for physicians. In the case of oligometastatic disease, surgery has a crucial role. In selected cases of a possible indolent progression of the malignancy, a surgical approach is recommended to control the disease. The management of this subset of patients should be performed in a multidisciplinary team in order to define the best strategy for each patient.Recent findingsThe implementation of optimizing surgical management has demonstrated better outcomes in terms of long-term survival with no detrimental ...
Source: Current Surgery Reports - Category: Surgery Source Type: research
Condition:   Carcinoma, Non-Small-Cell Lung Intervention:   Biological: Autologous Tcm cells immunotherapy Sponsors:   Beijing Friendship Hospital;   Newish Technology (Beijing) Co.,Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Education | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Toxicology | Universities & Medical Training